Neoplasm Metastasis clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for

  • 9-ING-41 in Patients With Advanced Cancers

    open to eligible people ages 18 years and up

    GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

    Orange, California and other locations

  • PF-07265807 in Participants With Metastatic Solid Tumors.

    Sorry, in progress, not accepting new patients

    A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

    Orange, California and other locations

Our lead scientists for Neoplasm Metastasis research studies include .

Last updated: